The company focuses on developing human parthenogenetic stem cells for therapeutic applications. This initial launch will focus on the company’s existing Lifeline Skin Care customers.
According to the CDC, osteoarthritis is the most common form of degenerative joint disease and affects approximately 630 million people around the globe. Technavio analysts predict that the global bone and joint supplements market will reach $3.3 billion by the end of 2023.
More articles on biologics:
How Dr. Kevin Stone helped Super Bowl champion Tracy Porter make a comeback — 6 details
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
